In addition, as there were more upcoming novel agents for EGFR-mutant NSCLC, such as ADCs, immune checkpoint inhibitors, and amivantamab, the heterogenicity of subsequent treatment of these patients can also interfere the OS. Here, EGFR is linked to non-small cell lung carcinoma.